TABLE 1.
The clinical and pathological characteristics of the 332 patients according to the adjuvant chemotherapy agents in the present study
| All, n (%) | Gemcitabine, n (%) | S‐1, n (%) | ||
|---|---|---|---|---|
| 332 (100) | 170 (100) | 162 (100) | p | |
| Sex | .440 | |||
| Male | 185 (56) | 91 (54) | 94 (58) | |
| Female | 147 (44) | 79 (46) | 68 (42) | |
| Age a | 66 (34–86) | 66 (44–84) | 66 (34–86) | .805 |
| ECOG performance status | .561 | |||
| 0 | 222 (67) | 111 (65) | 111 (69) | |
| 1 | 110 (33) | 59 (35) | 51 (31) | |
| Operative procedure | .053 | |||
| Pancreatoduodenectomy | 224 (67) | 121 (71) | 103 (64) | |
| Distal pancreatectomy | 105 (32) | 46 (27) | 59 (36) | |
| Total pancreatectomy | 3 (1) | 3 (2) | 0 (0) | |
| Combined portal vein resection | 96 (29) | 50 (29) | 46 (28) | .904 |
| Number of dissected lymph nodes a | 25 (1–81) | 26 (2–81) | 24 (1–77) | .404 |
| Residual tumor status | .751 | |||
| R0 | 286 (86) | 145 (85) | 141 (87) | |
| R1 | 46 (14) | 25 (15) | 21 (13) | |
| Primary tumor status b | .862 | |||
| T1–T2 | 36 (11) | 19 (11) | 17 (10) | |
| T3–T4 | 296 (89) | 151 (89) | 145 (90) | |
| Regional lymph node status b | .302 | |||
| N0 | 116 (35) | 64 (38) | 52 (32) | |
| N1 | 216 (65) | 106 (62) | 110 (68) | |
| CA19‐9 | .502 | |||
| ≤37 U/ml | 263 (79) | 132 (78) | 131 (81) | |
| >37 U/ml | 69 (21) | 38 (22) | 31 (19) | |
| Pathological stage b | .333 | |||
| IA | 17 (5) | 8 (5) | 9 (6) | |
| IB | 8 (2) | 6 (3) | 2 (1) | |
| IIA | 90 (27) | 49 (29) | 41 (25) | |
| IIB | 215 (65) | 107 (63) | 108 (67) | |
| III | 2 (1) | 0 (0) | 2 (1) |
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
a
Median (range).
b
Primary tumor status, regional lymph node status, and pathological stage according to the TNM Classification of Malignant Tumours, 6th edition.